Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis
NCT06589219Phase 1Completed
- Sponsor
- Calibr-Skaggs Institute for Innovative Medicines
- Start
- Aug 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CMR316 in idiopathic pulmonary fibrosis (IPF) (5 arms), sponsored by Calibr-Skaggs Institute for Innovative Medicines. Primary endpoints: Number of participants with adverse events at Day 50, Number of participants with clinically significant abnormal physical exam and vital signs at Day 50 and 3 more. Started Aug 2024; status: completed.
02
Drugs
CMR316
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06589219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06589219.